Hesham M Ismail HAMED

Dr. Hesham M Ismail HAMED

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in The American Journal of Pathology
Verified
Journal Article
Open access
ODOlivier M. Dorchies
Olivier M. Dorchies
JRJulie Reutenauer-Patte
Julie Reutenauer-Patte
EDElyes Dahmane
Elyes Dahmane
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
OPOlivier Petermann
Olivier Petermann
URUrs T. RUEGG
Urs T. RUEGG
Duchenne muscular dystrophy (DMD) is a severe disorder characterized by progressive muscle wasting,respiratory and cardiac impairments, and premature death. No treatment exists so far, and the identification of active substances to fight DMD is urgently needed. We found that tamoxifen, a drug used to treat estrogen-dependent breast cancer, caused remarkable improvements of muscle force and of diaphragm and cardiac structure in the mdx(5Cv) mouse model of DMD. Oral tamoxifen treatment from 3 weeks of age for 15 months at a dose of 10 mg/kg/day stabilized myofiber membranes, normalized whole body force, and increased force production and resistance to repeated contractions of the triceps muscle above normal values. Tamoxifen improved the structure of leg muscles and diminished cardiac fibrosis by~ 50%. Tamoxifen also reduced fibrosis in the diaphragm, while increasing its thickness,myofiber count, and myofiber diameter, thereby augmenting by 72% the amount of contractile tissue available for respiratory function. Tamoxifen conferred a markedly slower phenotype to the muscles.Tamoxifen and its metabolites were present in nanomolar concentrations in plasma and muscles,suggesting signaling through high-affinity targets. Interestingly, the estrogen receptors ERa and ERb were several times more abundant in dystrophic than in normal muscles, and tamoxifen normalized the relative abundance of ERb isoforms. Our findings suggest that tamoxifen might be a useful therapy for DMD.

19 November 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
EGElinam Gayi
Elinam Gayi
LNLaurence Neff
Laurence Neff
XMXènia Massana Muñoz
Xènia Massana Muñoz
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
MSMarta Sierra
Marta Sierra
LSLeonardo Scapozza
Leonardo Scapozza
X-linked myotubular myopathy (XLMTM, also known as XLCNM) is a severe congenital muscular disorder due to mutations in the myotubularin gene, MTM1. It is characterized by generalized hypotonia, leading to neonatal death of most patients. No specific treatment exists. Here, we show that tamoxifen, a well-known drug used against breast cancer, rescues the phenotype of Mtm1-deficient mice. Tamoxifen increases lifespan several-fold while improving overall motor function and preventing disease progression including lower limb paralysis. Tamoxifen corrects functional, histological and molecular hallmarks of XLMTM, with improved force output, myonuclei positioning, myofibrillar structure, triad number, and excitation-contraction coupling. Tamoxifen normalizes the expression level of the XLMTM disease modifiers DNM2 and PI3KC2B, likely contributing to the phenotypic rescue. Our findings demonstrate that tamoxifen is a promising candidate for clinical evaluation in XLMTM patients.

17 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
LSLeonardo Scapozza
Leonardo Scapozza
URUrs T. RUEGG
Urs T. RUEGG
ODOlivier M Dorchies
Olivier M Dorchies
Elevation of intracellular Ca2+, excessive ROS production and increased phospholipase A2 activity contribute to the pathology in dystrophin-deficient muscle. Moreover, Ca2+, ROS and phospholipase A2, in particular iPLA2, are thought to potentiate each other in positive feedback loops. NADPH oxidases (NOX) have been considered as a major source of ROS in muscle and have been reported to be overexpressed in muscles of mdx mice. We report here on our investigations regarding the effect of diapocynin, a dimer of the commonly used NOX inhibitor apocynin, on the activity of iPLA2, Ca2+ handling and ROS generation in dystrophic myotubes. We also examined the effects of diapocynin on force production and recovery ability of isolated EDL muscles exposed to eccentric contractions in vitro, a damaging procedure to which dystrophic muscle is extremely sensitive. In dystrophic myotubes, diapocynin inhibited ROS production, abolished iPLA2 activity and reduced Ca2+ influx through stretch-activated and store-operated channels, two major pathways responsible for excessive Ca2+ entry in dystrophic muscle. Diapocynin also prevented force loss induced by eccentric contractions of mdx muscle close to the value of wild-type muscle and reduced membrane damage as seen by Procion orange dye uptake. These findings support the central role played by NOX-ROS in the pathogenic cascade leading to muscular dystrophy and suggest diapocynin as an effective NOX inhibitor that might be helpful for future therapeutic approaches.

11 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
WIWeam W. Ibrahim
Weam W. Ibrahim
NANoha F. Abdelkader
Noha F. Abdelkader
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
MKMahmoud M. Khattab
Mahmoud M. Khattab
Though selective serotonin reuptake inhibitors (SSRIs) have been found to increase cognitive performance in some studies on patients and animal models of Alzheimer’s disease (AD), other studies have reported contradictory results, and the mechanism of action has not been fully described. This study aimed to examine the effect of escitalopram, an SSRI, in an experimental model of AD and to determine the involved intracellular signalling pathways. Ovariectomized rats were administered D-galactose (150 mg/kg/day, i.p) over ten weeks to induce AD. Treatment with escitalopram (10 mg/kg/day, p.o) for four weeks, starting from the 7th week of D-galactose injection, enhanced memory performance and attenuated associated histopathological changes. Escitalopram reduced hippocampal amyloid β 42, β-secretase, and p-tau, while increasing α-secretase levels. Furthermore, it decreased tumor necrosis factor-α, nuclear factor-kappa B p65, and NADPH oxidase, while enhancing brain-derived neurotrophic factor, phospho-cAMP response element binding protein, and synaptophysin levels. Moreover, escitalopram diminished the protein expression of the phosphorylated forms of c-Jun N-terminal kinase (JNK)/c-Jun, while increasing those of phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), glycogen synthase kinase-3β (GSK-3β), extracellular signal-regulated kinase (ERK) and its upstream kinases MEK and Raf-1. In conclusion, escitalopram ameliorated D-galactose/ovariectomy-induced AD-like features through modulation of PI3K/Akt/GSK-3β, Raf-1/MEK/ERK, and JNK/c-Jun pathways.

1 April 2018 in Chimia
Verified
Journal Article
Open access
EGElinam Gayi
Elinam Gayi
LNLaurence A. Neff
Laurence A. Neff
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
URUrs T. Ruegg
Urs T. Ruegg
LSLeonardo Scapozza
Leonardo Scapozza
ODOlivier M. Dorchies
Olivier M. Dorchies
Drug discovery is a long, expensive and risky process. Evaluating drugs that have already been proved safe for use in humans and testing them for a new indication greatly reduces the time and monetary costs involved in finding treatments for life-threatening conditions. Here tamoxifen, a drug that is used for the treatment of breast cancer, is investigated in a mouse model of Duchenne muscular dystrophy. Tamoxifen was efficacious in countering the symptoms of the disease without affecting the underlying genetic cause. Based on these results, tamoxifen has been tested in other forms of muscle disease with success. Drug repurposing may not only be a cost-effective manner for treating a variety of diseases, it may also help us uncover common mechanisms between conditions that were previously thought to be unrelated.

20 March 2018 in Expert Opinion on Orphan Drugs
Verified
Journal Article
Closed access
HHHesham M Ismail HAMED
Hesham M Ismail HAMED
ODOlivier M. Dorchies
Olivier M. Dorchies
LSLeonardo Scapozza
Leonardo Scapozza
Introduction: Muscular dystrophies encompass a heterogeneous group of rare genetic neuromuscular disorders affecting locomotor, cardiac and respiratory muscles. These diseases are mostly debilitating progressive disorders with poor prognosis. Despite the discovery of the genetic causes and in depth understanding of the pathophysiological changes that take place in these disorders, efficacious therapies are still to be developed. The expected price of innovative therapies that are reaching the market for such rare disorders are of concern. Areas covered: For this review, Duchenne muscular dystrophy is used as an example of these disorders. Clinical features, pathophysiological processes, socioeconomic impact, investigational and recently marketed therapeutic modalities for this disease and their price tag are discussed. Tools to circumvent cost and time for therapeutic development for such disorders are described highlighting the potential of this pathway and the obstacles to overcome. Expert opinion: Repurposing already existing drugs with a well-studied pharmacokinetic, pharmacodynamic and safety profile holds a tremendous promise in delivering efficacious therapies in a cost controlled and timely manner to patients suffering life-threatening diseases who cannot wait for a classical drug development cycle. The use of this path is accelerated by incentives, guidance and protection provided by holding an orphan drug designation status.